VINCERX PHARMA INC. - COMMON STOCK

Vincerx Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

28 Mar 2023 15:05:00 By Nasdaq GlobeNewswire

Vincerx Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023

14 Mar 2023 15:35:00 By Nasdaq GlobeNewswire

Vincerx Pharma to Participate at the SVB Securities Global Biopharma Conference

06 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

Vincerx Pharma Announces FDA Safe to Proceed Letter for Investigational New Drug (IND) Application for its αVβ3 Small Molecule-Drug Conjugate (SMDC) VIP236

13 Dec 2022 08:29:13 By Nasdaq GlobeNewswire

Vincerx Pharma Provides American Society of Hematology Annual Meeting 2022 Poster Highlights on Enitociclib in Multiple Tumor Types

12 Dec 2022 15:05:00 By Nasdaq GlobeNewswire

Vincerx Pharma Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022

11 Dec 2022 09:05:00 By Nasdaq GlobeNewswire

Vincerx Pharma Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

10 Nov 2022 15:05:02 By Nasdaq GlobeNewswire

Vincerx Pharma Announces Upcoming Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting 2022

03 Nov 2022 08:05:00 By Nasdaq GlobeNewswire

Vincerx Pharma Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

11 Aug 2022 15:05:01 By Nasdaq GlobeNewswire

Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Lymphoma at the European Hematology Association 2022 Congress

10 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Vincerx Pharma Provides Key Strategic Update

06 Jun 2022 15:05:00 By Nasdaq GlobeNewswire

Vincerx Pharma Reports First Quarter 2022 Financial Results and Provides a Corporate Update

12 May 2022 15:05:02 By Nasdaq GlobeNewswire

Vincerx Pharma Presents Preclinical and Preliminary Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Gynecologic Malignancies at the American Association for Cancer Research (AACR) Annual Meeting 2022

08 Apr 2022 12:05:00 By Nasdaq GlobeNewswire

Vincerx Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

29 Mar 2022 07:00:03 By Nasdaq GlobeNewswire

Vincerx Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022

08 Mar 2022 15:35:00 By Nasdaq GlobeNewswire

Vincerx Pharma to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

09 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Vincerx Pharma Publishes Preclinical Data Demonstrating Therapeutic Potential of Small Molecule-Drug Conjugate VIP236 in the Journal Cancers

03 Feb 2022 07:30:00 By Nasdaq GlobeNewswire

Vincerx Pharma Announces First Patient Dosed in Phase 1 Dose-Escalation Study of VIP152 in Relapsed or Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

17 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Vincerx Pharma Presents Data on PTEFb/CDK9 Inhibitor VIP152 in DLBCL and CLL at the 63rd American Society of Hematology Annual Meeting

11 Dec 2021 14:30:00 By Nasdaq GlobeNewswire

Vincerx Pharma Receives Orphan Drug Designation from European Commission for VIP152 for the Treatment of Diffuse Large B-Cell Lymphoma

07 Dec 2021 07:00:01 By Nasdaq GlobeNewswire